;">The MD Anderson Cancer Center recently announced the long-term follow-up results of a Phase II study of the R2 regimen in the treatment of FL. The main results are now summarized as follows for the reference of readers.
Spectral MD, a medical device company, completed a $27 million financing
Time of Update: 2021-02-25
Spectral MD plans to use this round of funding to develop DeepView, an AI-driven wound imaging system, primarily to diagnose burns and help improve their clinical efficacy.
J Clin Oncol: Eprenetapopt combined with Aza cytosine to treat TP53 mutant MDS and AML
Time of Update: 2021-02-24
Regardless of the treatment, the prognostics of TP53 mutation (TP53m) bone marrow prognostic abnormal syndrome (MDS) and acute myeloid leukemia (AML) were very poor, with only 40% remission rate (full remission rate of 20%) for Azatide (AZA
J Clin Oncol: Eprenetapopt combined with Aza cytosine to treat TP53 mutant MDS
Time of Update: 2021-02-01
About 20% of patients with TP53 mutant bone marrow growth abnormal syndrome (MDS) receive complete remission (CR) after treatment with demthylation drugs.
Blood: Short telomere length predicts non-recurrence mortality after stem cell transplantation in MDS patients
Time of Update: 2021-01-14
length in blood samples of 1,514 MDS patients prior to transplantation and assessed the correlation between telomere length and MDS disease characteristics and transplant prognostics. analysis of the correlation between telomere length and age
J Clin Oncol: Intensive conditioning solutions do not improve the prognostic prognostics of allo-HSCT in older patients with high-risk AML/MDS
Time of Update: 2021-01-14
overall, the enhanced RIC conditioning program, FLAMSA-Bu, does not improve the prognostication of high-risk AML or MDS elderly patients receiving transplant treatment, regardless of THED status prior to transplantation.
Deqi ATG-016 treatment MDS has been approved by Phase II clinical trials in China
Time of Update: 2021-01-01
transformation to acute myeloid leukemia. patients with bone marrow-growth abnormal syndrome, where de-methylation drugs are difficult to treat, the medium total survival period (OS) is only 4-6 months, and follow-up treatment options are limited
Clin Cancer Res: Effects of acute and chronic graft resistance to MDS on long-term prognosis after hematogenes transplantation.
Time of Update: 2020-10-13
multivariable analysis showed that in patients with low-risk MDS, the grade or severity of acute and chronic GVHD had no significant effect on total mortality, recurrence rate, or non-mortality (NRM).
Blood: Machine learning reveals the correlation between MDS genotypes and morphological characteristics.
Time of Update: 2020-10-12
study sequenced 1,079 MDS patients and analyzed bone marrow morphological changes and other clinical features.
Gilead anti-CD47 monoantigen resistance was identified by the FDA breakthrough therapy to treat MDS.
Time of Update: 2020-10-03
references: sgiad's Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA File Therapy Designation for Treatment of Myelodysplastic Syndrome.
Blood: Effects of TP53 mutations on MDS and secondary AML prognosation.
Time of Update: 2020-08-22
Sotic cell gene mutations are a key determinant of prognosis in patients with bone marrow proplation abnormal syndrome (MDS) and secondary acute myeloid leukemia (SAML).
Express . . . Strong teamed up to develop innovative cancer therapies with Sanofi and MD Anderson Cancer Center.
Time of Update: 2020-07-17
The alliance will lead biomarker-driven clinical studies to better understand how new cancer drugs work, combined with the MD Anderson Cancer Center's clinical trial infrastructure and Sanofi's experimental treatment pipeline.
Sanofi and MD Anderson Cancer Center jointly develop innovative cancer therapies
Time of Update: 2020-07-16
"Our goal is to improve outcomes for a range of patients with difficult cancer, and the best way to achieve this is through a deep understanding of how new drugs work," said Dr. Peter Adamson, Head of Global Development for Oncology and Pediatric
Tisitabin United Semi-Compatible Lymphocyte Infusion Treatment MDS Allogeneic Hematopoietic Stem
Time of Update: 2020-07-13
Ishee-based hematotransplantation (allogeneic stem cellation, allo-HCT) is considered the only option for treating myelodysplastic syn -drome, MDS? However, relapse is the main reason for the failure of HCT treatment, Molina
Blood: Pharmacokinetics, Efficacy and Safety of Oral Cedazuridine/Tisitabin Therapeutics MDS and CMML
Time of Update: 2020-06-24
This study is a Phase 2 clinical trial designed to compare the exposure, demethylation activity and safety of the cedazuridine 100mg/Ditathabin 35mg and standard Sitabin 20mg/m2(IV) treatment for the first two courses of treatment
FDA approves for launch of Therapeutics MD's BIJUVA ™ capsule (1 mg/100 mg)
Time of Update: 2020-06-11
in line with FDA guidelines, the common primary therapeutic endpoint in this supplementary trial is a change in the value and severity of hot flashes in the 4th and 12th weeks in comparison to placebo.
FDA grants FAST-TRACK STATUS FOR CUTX-101 TREATMENT OF MD
Time of Update: 2020-06-11
In addition to CUTX-101, Cyprium is also developing a gene therapy based on adeno-related virus (AAV) AAV-ATP7A, which is designed to deliver the correct version of the ATP7A gene to Patients with MD.
Pross MD launches Bijuva (estradiol and progesterone capsules, 1mg/100mg) in the U.S. market
Time of Update: 2020-06-10
FDA ( at the end of October 2018 and is the first and only biologically identical (bio-identical) hormone combination therapy that binds estradiol and progesterone to a single oral capsule.